CERTARA

CERTARA'S ENVIRONMENTAL, SOCIAL, AND GOVERNANCE (ESG) REPORT

Contents

INTRODUCTION

HEALTH AND SOCIAL IMPACT OF OUR SOFTWARE AND SERVICES

OUR PEOPLE AND CULTURE

CORPORATE GOVERNANCE AND COMPLIANCE

OUR ENVIRONMENTAL IMPACT

Introduction

CEO LETTER TO OUR STAKEHOLDERS

At Certara, our mission is to accelerate medicines to patients using biosimulation software, technology, and services. We inform critical decisions throughout the drug development process to not only deliver efficiencies but also to help increase drug safety and efficacy for the benefit of patients worldwide.

We tackle the toughest challenges in drug development with our cutting-edge technology and expert team of more than 1,400 employees worldwide. Our biosimulation software helps to predict how a drug works in different populations, such as infants, the elderly and people with co-morbidities. Biosimulation can be used to streamline clinical trials and enroll fewer patients. Certain studies, such as drug-drug interaction studies, may be waived altogether using our biosimulation software. With biosimulation, we can help to get safe and effective drugs developed and approved while minimizing testing of investigational drugs on animals and humans.

We also provide an integrated suite of technology-driven services, ranging from drug discovery and development to regulatory submission support and market access consulting. Our work spans a wide range of therapeutic areas from oncology to rare diseases and various modalities, including small molecules, biologics, and gene therapy. Since 2014, our clients, who use our software and technology-driven services, received 90% of new drug approvals by the FDA, excluding diagnostics.

We have a proven record of successfully acquiring and integrating software and services companies. Since 2013, we have acquired 20 companies of which 13 included software or technology such as Simcyp, the core of our mechanistic biosimulation platform, Pinnacle 21, which enhances our software offerings in data management and the regulatory drug approval process, and Vyasa, which brings state-of-the-art AI capabilities to our end-to-end platform. In 2023, we acquired three new businesses including Formedix, which added a metadata repository and clinical data flow automation to our data platform. Additionally, we acquired Applied Biomath, a company focused on QSP to expand and complement Certara's existing QSP capabilities.

In 2023, Certara's Environmental, Social and Governance ("ESG") strategy focused on three key areas:

- **Accelerating crucial medicines to patients**
  Accelerating medicines is our mission and why we are passionate about coming to work every day. Through our science-and-technology-based approach, we set precedents and expand boundaries in trusted collaboration with our customers. We have worked with nearly 2,400 life sciences companies and academic institutions and have collaborated on more than 8,000 customer projects in the last decade across a variety of therapeutic areas ranging from cancer and hematology to diabetes and hundreds of rare diseases.
- **Advancing scientific thought leadership and knowledge sharing**
  Our expert global team not only contributes to software development and clients' drug programs, but also dedicates expertise and time to author publications and create and deliver posters and presentations at conferences. In addition, Certara provides software licenses to hundreds of academic institutions worldwide for teaching purposes and academic research.
- **Increasing engagement with employees**
  Our employees are our competitive advantage and create our success. With our growing global team, we have made purposeful efforts to increase engagement with employees and provide support. We are deeply committed to providing flexibility and resources to help our team thrive at Certara.

While we are proud of the progress we have made, we are excited about the road ahead as we continue to further our ESG initiatives. We believe that there is significant opportunity to continue expanding our positive impact worldwide. We can and must think differently about how we develop medicines, better and faster to improve and help save patient lives worldwide.

William F. Feehery, PhD
CEO

Introduction

ESG PROGRAM GOVERNANCE

CERTARA IS COMMITTED TO UNDERSTANDING, MONITORING, AND MANAGING OUR SOCIAL,ENVIRONMENTAL, AND ECONOMIC IMPACT TO SUPPORT SUSTAINABLE DEVELOPMENT.

This sense of corporate social responsibility manifests itself in several ways, including:

- Conducting our business in a responsible, honest, and ethical manner
- Acting as responsible stewards of the environment
- Ensuring a safe and healthy working environment for our employees
- Supporting universal human rights and
- Respecting and supporting the diverse cultures and individuals that form our Company.

Our Board of Directors, through the Nominating and Corporate Governance Committee, is ultimately responsible for our ESG strategy. The day-to-day management and implementation of our ESG programs are governed by our ESG Steering Committee. The ESG Committee supports the Company's on-going commitment to health and safety, corporate social responsibility, corporate governance, sustainability, charitable giving, environmental stewardship, and other public policy matters relevant to the Company. We reference and leverage sustainability standards applicable to our business, including the standards established by the Sustainability Accounting Standards Board ("SASB"), and incorporate the ten principles of the UN Global Compact into our ESG strategy.

The ESG Steering Committee is a cross-functional management committee, responsible for:

- Proposing general strategy relating to ESG matters
- Developing, implementing, and monitoring initiatives and policies based on that strategy
- Overseeing communications with employees, investors and stakeholders with respect to ESG matters
- Monitoring and assessing developments relating to, and improving the Company's understanding of ESG matters
- Providing efficient and timely disclosure of ESG matters to internal and external stakeholders.

The Committee currently consists of our Chief Human Resources Officer, General Counsel, and Chief Marketing Officer.

Health and Social Impact of Our Software and Services

OVERVIEW

$34.1M
2023 R&D SPEND (10% OF REVENUE)

32
NEW SOFTWARE APPLICATIONS AND UPGRADES IN 2023

8,000+
CUSTOMER PROJECTS SUPPORTED IN THE LAST DECADE

300+
REGULATORY SUBMISSIONS IN THE PAST 5 YEARS

WE ACCELERATE MEDICINES TO PATIENTS USING OUR PROPRIETARY BIOSIMULATION TOOLS. Our biosimulation technology is a computer simulation of what happens when a dose of a drug is introduced to a human body. It is a large, complex model that captures the transport of the drug in the body, the concentration over time in places where you want the drug or where you may not want the drug and how it gets metabolized and excreted.

In SASB's standards for the Biotech and Pharmaceutical sector, the safety of clinical trial participants is one key initiative. Our biosimulation software has many different uses throughout drug development to help increase safety and efficacy of drugs during their use in clinical trials and in the real world, post regulatory approval. For example, in the nonclinical phase, our biosimulation software with animal models for rat, mouse, dog and monkey, can be used to reduce animal testing. Then, before starting a Phase I trial, it is critical to determine the right "first in human" dose. This is typically informed by lab and animal trial data, but biosimulation can give a more refined and accurate estimate on which to base the trial. In 2021, we conducted a first-in-human dosing workshop, teaching participants how to use models within the Simcyp Simulator to prioritize compounds for progress from nonclinical to Phase 1 clinical development using information available in early drug discovery.

As the drug moves into Phases 2 and 3, biosimulation is used to determine the right dose for the right patient. A dose that is too high could lead to side effects and safety issues. A dose that is too low may not be as effective as needed. Furthermore, biosimulation can streamline clinical studies, requiring fewer study subjects, and in some cases, biosimulation can waive a clinical study altogether, in particular drug-drug interaction studies.

Providing access to medicines is another top priority that we aim to achieve in two distinct ways. First, we can model pharmacological effects of a drug across many different human populations and profiles with our biosimulation software. There are certain populations that are much more challenging to enroll in clinical studies, such as children and pregnant women. By being able to model how the drug works in virtual populations, we are able to predict the optimal dose for these special populations and inform the drug label. To date, the Simcyp Simulator has generated results that inform more than 350 label claims for more than 110 approved drugs helping to mitigate the cost and time required with clinical trials.

AI and machine learning technologies are being incorporated across our software and services portfolios providing opportunities to expand the number of data sources utilized, better predict outcomes, and streamline reporting.

In 2023, we extended the capabilities of MIDD and regulatory offerings with the launch of an AI platform designed for life sciences, Certara.AI. It is a secure, flexible platform for deploying life science specific Generative Pre-Trained Transformers ("GPTs") across an organization's data, enabling faster search, connectivity, and content generation.

Health and Social Impact of Our Software and Services

OVERVIEW

In addition, generative AI is revolutionizing how regulatory writers approach the first draft of submissions. Leveraging the expertise of Certara.AI, our CoAuthor software features a specialized GPT to accelerate the drafting of documents. We believe that AI predictive models will continue to enhance the accuracy and usefulness of biosimulation models and be utilized broadly across drug development.

In later stages, biosimulation is frequently used in drug-drug interaction studies since we can use biosimulation to test many different combinations of drugs to determine which may cause adverse effects if taken together.

Biosimulation can also be instrumental in informing pediatric translational studies, in which our customers and we use data from adult clinical trials to predict the dose for children, from neonates to teenagers.

Our software portfolio also includes regulatory technologies, which help to increase the quality of and expedite patient safety narratives and other regulatory documents as well as the regulatory submission process. Regulatory requirements across countries and regions vary and are continuously evolving. The regulatory process requires significant effort and attention to detail. Non-compliance with regulatory standards or lack of quality can delay the approval process. At Certara, we have developed a suite of regulatory technologies that we and our clients use to save time and resources during regulatory preparation and submission.

SIMCYP SIMULATOR-SUPPORTED FDA APPROVED NOVEL DRUGS

ONCOLOGY	AbbVie	Venclexta ***(venetoclax)***	EMD Serono	Tepmetko ***(tepotinib hydrochloride)***	Novartis	Vijoice ***(alpelisib)***
	Agios	Tibsovo *(ivosidenib)*	Genentech	Alecensa ***(alectinib)***	Novartis	Rydapt ***(midostaurin)***
	Amgen	Blincyto ***(blinatumomab)***	Genentech	Cotellic ***(cobimetinib)***	Novartis	Tabrecta ***(capmatinib)***
	Amgen	Lumakras ***(sotorasib)***	Genentech	Gavreto® ***(pralsetinib)***	Novartis	Zykadia ***(ceritinib)***
	Ariad	Alunbrig ***(brigatinib)***	Genentech	Polivy ***(polatuzumab vedotin-piiq)***	Novartis	Jakavi ***(ruxolitinib)***
	Ariad (Takeda)	Iclusig ***(ponatinib)***	Genentech	Rozlytrek ***(entrectinib)***	Pfizer	Daurismo ***(glasdegib)***
	AstraZeneca	Calquence ***(acalabrutinib)***	Incyte	Pemazyre ***(pemigatinib)***	Pfizer	Ibrance® ***(palbociclib)***
	AstraZeneca	Lynparza ***(olaparib)***	Janssen	Balversa ***(erdafitinib)***	Pfizer	Bosulif ***(bosutinib)***
	AstraZeneca	Tagrisso ***(osimertinib)***	Janssen	Erleada ***(apalutamide)***	Pfizer	Lorbrena ***(lorlatinib)***
	AstraZeneca	Truqap® ***(capivaserib)***	Lilly	Retevmo ***(selpercatinib)***	Pharmacyclics	Imbruvica ***(ibrutinib)***
	Beigene	Brukinsa ***(zanubrutinib)***	Lilly	Verzenio ***(abemaciclib)***	Puma	Nerlynx® ***(neratinib)***
	Biohaven	Nurtec ***(rimegepant)***	Loxo	Jaypirca ***(pirtobrutinib)***	Sanofi	Jevtana ***(cabazitaxel)***
	BluePrint Medicines	Ayvakit ***(avapritinib)***	Loxo Oncology	Vitrakvi ***(larotrectinib)***	Seattle Genetics	Tukysa ***(tucatinib)***
	Celgene	Inrebic ***(fedratinib hydrochloride)***	Menarini/Stemline	Orserdu ***(elacestranto)***	Spectrum	Beleodaq ***(belinostat)***
	Daiichi Sankyo	Turalio ***(pexidartinib)***	Mirati	Krazati ***(adagrasib)***	Springworks	Ogsiveo® ***(nirogancent)***
	Daiichi Sankyo	Ezharmia ***(valmetostat tosilate)***	Novartis	Farydak ***(panobinostat)***	Takeda	Exkivity ***(mobocertinib)***
	Daiichi Sankyo	Vanflyta® ***(quizartinib dihydrochloride)***	Novartis	Kisqali ***(ribociclib succinate)***	Takeda	Fruzaqla® ***(fruquintinib)***
	Deciphera	Qinlock ***(ripretinib)***	Novartis	Scemblix ***(asciminib)***	Taiho	Lytgobi ***(futibatinib)***
	Eisai	Lenvima ***(lenvatinib)***	Novartis	Odomzo ***(sonidegib)***	Verastem	Copiktra ***(duvelisib)***
RARE DISEASE	Agios	Pyrukynd ***(mitapivat)***	Intercept	Ocaliva ***(obeticholic acid)***	Peloton/Merck	Welireg ***(belzutifan)***
	AkaRx (Eisai)	Doptelet ***(avatrombopag maleate)***	Ipsen	Sohonus® ***(palovarotene)***	PTC Therapeutics	Emflaza ***(deflazacort)***
	AstraZeneca	Koselugo ***(selumetinib)***	Kadmon	Rezurock ***(belumosudil)***	Sanofi Genzyme	Cerdelga ***(eliglustat tartrate)***
	Aurinia	Lupkynis ***(voclosporin)***	Merck	Welireg ***(belzutifan)***	Travere	Filspari ***(sparsentan)***
	Genentech	Enspryng ***(satralizumab)***	Mirum	Livmarli ***(maralixibat)***	Vertex	Symdeko ***(tezacaftor/ivacaftor)***
	Genentech	Evrysdi ***(risdiplam)***	Mitsubishi Tanabe	Dysval ***(Valbenazine)***	Vertex	Trikafta ***(elexacaftor/ivacaftor/tezacaftor)***
	Global Blood Therapeutics	Oxbryta ***(voxelotor)***	Novartis	Isturisa ***(osilodrostat)***		
CENTRAL NERVOUS SYSTEM	AbbVie	Rinvoq ***(upadacitinib)***	Eisai	Dayvigo ***(lemborexant)***	Lilly	Reyvow ***(lasmiditan succinate)***
	AbbVie	Qulipta ***(atogepant)***	Idorsia	Quviviq ***(daridorexant)***	Novartis	Mayzent ***(siponimod fumaric acid)***
	Alkermes	Aristada ***(aripiprazole lauroxil)***	Janssen	Ponvory ***(ponesimod)***	Pfizer	Zavzpret ***(zavegepant)***
	Alkermes	Lybalvi ***(olanzapine/samidorphan)***	Kyowa Kirin	Nourianz ***(istradefylline)***	UCB	Briviact ***(brivaracetam)***
INFECTIOUS DISEASE	Gilead	Vexlury ***(remdesivir)***	Merck	Prevymis ***(letermovir)***	Pfizer	Paxlovid® ***(nirmatrelvir, ritonavir)***
	Gilead	Veklury (***remdesivir***)	Nabriva	Xenleta ***(lefamulin acetate)***	Tibotec	Edurant ***(rilpivirine)***
	Janssen	Olysio ***(simeprevir)***	Novartis	Egaten ***(triclabendazole)***	ViiV	Cabenuva Kit ***(cabotegravir/rilpivirine)***
	Merck	Pifeltro ***(doravirine)***				
GASTROENTEROLOGY	AstraZeneca	Farxigo ***(dapaglifoxin)***	Phathom	Voquezna TriplePak (*vonoprazan/amoxicillin/clarithromycin*)	Shire	Motegrity ***(prucalopride)***
	AstraZeneca	Movantik ***(naloxegol)***	Shionogi	Symproic ***(naldemedine)***		
	Helsinn	Akynzeo ***(fosnetupitant/palonosetron)***				
CARDIOVASCULAR	Actelion (J & J)	Opsumit ***(macitentan)***	Johnson & Johnson	Xarelto ***(rivaroxaban)***		
	BMS	Camzyos ***(mavacamten)***	Pfizer	Revatio ***(sildenafil)***		
ENDOCRINE	AbbVie	Orilissa ***(elagolix)***	Janssen	Invokana ***(canagliflozin)***	Merck	Steglatro ***(ertugliflozin)***
	Astellas	Veozah® ***(fezolinetant)***	Lilly	Olumiant ***(baricitinib)***		
	Esperion	Nexetol ***(bempedoic acid)***	Lilly	Mounjaro ***(tirzepatide)***		
OTHER	Galderma	Aklief ***(trifarotene)***	Takeda	Livtencity ***(maribavir)***		

Updated March. 2024

Health and Social Impact of Our Software and Services

R&D INVESTMENT AND INNOVATION

WE INVESTED $34.1M IN R&D OR 10% OF OUR REVENUE IN 2023, RESULTING IN THE LAUNCH OF 32 NEW SOFTWARE PRODUCTS AND UPDATES. Certara's global team of 220+ software developers and technology experts produce a regular cadence of product releases. Our software delivers new capabilities to accelerate our clients' drug development programs and improve patient lives.

In 2022, we acquired Vyasa Analytics, LLC. Vyasa provides scalable deep-learning software that allows life sciences organizations to ask and answer complex questions across structured and unstructured biomedical information. The acquisition brought state-of-the-art artificial intelligence (AI) capabilities to Certara's end-to-end software platform.

Incorporating AI into our products allows us to expand our leadership in drug research and development. For example, we launched Co-Author Generative AI Regulatory Writing Software in 2024. CoAuthor is an advanced writing platform designed for medical writers. It combines generative AI, document templates, and structured content authoring tools. CoAuthor accelerates creating regulatory documents while maintaining a "human in the loop" approach to using generative AI.

Medical writing is critical to drug development. It relies on manual processes which haven't changed significantly in 20 years. Drug development pipelines increasingly comprise precision medicine therapies that depend on advanced biomedical knowledge.

Today's medical writers must translate complex study data into documents that contextualize research results for different audiences. They need better ways to synthesize numerous data sources and connect them to their documents.

Built by writers, for writers, CoAuthor is easy to use. It combines a life science specialized, secure, client-specific GPT with structured content authoring and comprehensive regulatory writing templates. With CoAuthor, medical writers can streamline document drafting, allowing more time for content curation, collaboration, and quality control. Fully integrated with Microsoft Word, CoAuthor enables writers to use familiar tools and processes while ensuring consistency and quality.

Certara clients can leverage CoAuthor as a comprehensive regulatory writing solution across the enterprise. With CoAuthor, medical writers can decrease the time to first draft by at least 30% while using the generated content in the ways that they decide are best.

In 2023, we also acquired Applied Biomath. This company provides biosimulation support to help accelerate and de-risk pharmaceutical research and development. Certara and Applied Biomath are the largest team of experts in quantitative systems pharmacology (QSP). Researchers use this biosimulation method across the development lifecycle to predict endpoints, biomarkers, and the most effective dosing regimen.

Nine out of ten new therapies that enter the clinic do not achieve regulatory approval or commercialization. The primary reason is due to lack of efficacy or unmanageable toxicity. The use of QSP methodology has grown in recent years as a strategy to de-risk drug development. QSP combines computational modeling and experimental data to examine the relationships between a drug, the biological system, and the disease process. The resulting insights help scientists answer critical development questions including which patient populations are most likely to respond to novel therapies.

Applied Biomath and Certara have the scientific and computational expertise to industrialize QSP biosimulation methods. Our respective QSP businesses are complementary concerning clients, geographic location, indications, and expertise. Certara's existing biosimulation and AI portfolios will also help make QSP more widely available and accessible across the industry.

"CoAuthor has truly changed the writing process for safety narratives. Our team is able synthesize safety information efficiently while collaborating with sponsors to expedite timelines and increase consistency, ultimately assuring quality in the drug approval process."

Demetrius Carter
SVP, Services Operations
Regulatory Services

Our People and Culture

OUR CULTURAL VALUES

CERTIFIED AS A

GREAT PLACE TO WORK!

THREE YEARS IN A ROW!!

"Every day and in everything we do, we embrace idea generation, trust and support each other to think creatively and work together to improve the lives of patients everywhere."

– William Feehery, CEO



23

GLOBAL REGULATORY AUTHORITIES LICENSE CERTARA'S BIOSIMULATION SOFTWARE

At Certara, we recognize that our success would not be possible without the valuable contributions of our workforce. As such, **WE ARE COMMITTED TO INVESTING IN OUR PEOPLE AND FOSTERING AN ENGAGED WORKFORCE** that exemplifies some of our cultural tenets of innovation, collaboration, customer impact and scientific excellence.

INNOVATION

Certara is at the forefront of innovation in science and technology with a long history of firsts led by our team of experts, who are passionate about improving and accelerating the drug development process. Certara has more than 430 employees who hold doctorate degrees – PhDs, PharmDs and MDs. We highly value scientific curiosity, method, and rigor. Certara actively encourages curiosity and innovation through multidisciplinary work teams of scientists, modelers, mathematicians, regulatory experts and developers working together on research and software projects.

24,000

STUDIES USED THE PINNACLE 21 PLATFORM TO ENSURE COMPLIANCE WITH FDA SUBMISSION STANDARDS

For example, physiologically based pharmacokinetic (PBPK) modeling and simulation has become an established approach to assess drug-drug interaction (DDI) liabilities involving CYP enzymes, with transporters and/or absorption-related mechanisms. In addition, the use of PBPK modeling in specific populations such as organ impairment populations has been recently highly encouraged by the US FDA.

Successful application of PBPK models during regulatory review can be used in lieu of clinical trials and to inform the drug product label. In the recent NDA submission of asciminib (Scemblix®) by Novartis, PBPK simulations using Certara's Simcyp Simulator replaced over 10 clinical pharmacology studies. This technology also played an instrumental role in the approval of two additional doses by the US FDA with no additional clinical pharmacology studies at the date of approval. We continue to invest in expanding biosimulation models to help enable safer, faster and more cost-effective generic drug product development.

Our People and Culture

OUR CULTURAL VALUES

As a company with a rich scientific heritage and culture, our staff is committed to sharing lessons learned and best practices with each other and the industry. We are all innovators at Certara, no matter what our roles, and we address challenges with an innovative mindset and actively foster a culture that supports the application of new ideas. Our people enjoy the scientific freedom to explore novel ideas, develop groundbreaking research, and act as leaders in the scientific community. As a result, Certara has an exceptional presence at major scientific conferences, participating in presentations and poster sessions, exhibiting and sponsoring events.

COLLABORATION

Certara's culture encourages camaraderie and collaboration. Our staff endeavors to make new employees part of our team right from the start. We have developed manager onboarding specifically for this purpose, and we guide new employees with activities in preparation for their arrival and then align on goals for their orientation day, first week and first 60 days. Our onboarding also outlines the advantages of mentoring and provides new employees with a mentor to help them get guidance during this crucial learning phase.

"Encouraging employees to share their knowledge at conferences and through scientific publications is a top priority at Certara. Knowledge sharing among our experts, partners and the industry harnesses our collective expertise to solve the most complex problems in drug development.

– Rona Anhalt, Chief Human Resources Officer

We also value having approachable senior managers and human resources staff to build our culture and support our employees with day-to-day issues. Our priority is to build strong relationships across our employee base and ensure that all employees have the support and resources needed to succeed and achieve high levels of engagement. With our digital learning library, employees have access to a variety of courses, in addition to our broader offerings, to support their overall wellbeing, enhance their sense of connectedness, and foster continued personal and professional development.

CUSTOMER IMPACT

Certara provides employees with a broad range of collaborative customer experiences. For example, our Simcyp R&D team runs consultancy projects and provides workshops and training classes, participates in grant writing, and interacts with clients through our industry consortia. Underscoring this point, Certara is the founder of three industry consortia in which biopharmaceutical companies collaborate in a pre-competitive environment to develop best practices and progress modeling and simulation.

The Simcyp Consortium, formed 25 years ago, now has over 30 leading biopharmaceutical companies as members and is a global authority on mechanistic, physiologically-based pharmacokinetic ("PBPK") modeling and simulation. The member companies work together to progress model-informed drug development and inform the annual updates and new features to Certara's Simcyp PBPK Simulator. Eleven leading regulatory agencies, including the FDA and Japan's Pharmaceuticals and Medical Devices Agency, have also adopted the Simcyp Simulator

Our People and Culture

OUR CULTURAL VALUES

Certara's Simcyp Consortium proved so successful that it became the model for two additional pre-competitive consortia. Certara is now working with leading biopharmaceutical companies to develop immunogenicity and immuno-oncology models.

The Immunogenicity Consortium members set out to build a mechanistic model of the human immune system because they wanted to be able to predict when administering a biological therapeutic, such as an antibody, would generate an undesired immunogenic response. Immunogenicity is a challenge for biologic therapies, because it can cause adverse events. This work underscores how Certara prioritizes customer impact and serves as a reminder that we must always work to address even the broadest and most challenging therapeutic obstacles.

SCIENTIFIC EXCELLENCE

At Certara, scientific excellence is in our DNA. It guides our purpose of transforming drug development through unparalleled science, software and services and fuels our mission of "Accelerating Medicines Together."

We were honored to have 12 of our Certara scientists recognized in the top 2% of cited scientists based on standard citation metrics published by Elsevier and Stanford University in 2024. In further support of building scientific excellence for future generations, Certara hosts an annual Simcyp Scientific Academic Awards program, which celebrates the Simcyp Simulator's effective use in research and in teaching new scientists. More than 100 academic institutions use the Simcyp Simulator for biosimulation teaching and research, so it is a very competitive program. Awards are given for the Most Informative Scientific Report and Most Effective Teaching Application. Eligible institutions can also apply for funding for a research project through Certara's Grant and Partnership Scheme, which covers either a PhD or post-doctoral research program every year. Certara staff also continuously liaise with the winning organization on training and research.

To help ensure that resources do not limit biosimulation research advances, Certara provides 100 academic and non-profit organizations with more than 2,000 complimentary licenses to our Simcyp Simulator, as well as licenses to Phoenix. Certara also finds other ways to support new scientists, such as helping to fund the Population Approach Group in Europe Student Sponsorship, which enables student presenters at the PAGE Annual Meeting to attend the conference. Furthermore, we launched the Certara New Investigator Awards in association with the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists to recognize graduate investigators excelling in clinical and experimental pharmacology and toxicology and supporting scientific excellence.

Certara has collaborated with scientists in the US, UK, China, Japan, and the Netherlands to create 9 Academic Centers of Excellence to teach the next generation of pharmaceutical scientists. Certara provides faculty, students, and post-doctoral researchers at each Center of Excellence with Phoenix software licenses at no cost to support their coursework, academic research, and collaboration on projects with Certara. The Centers of Excellence then share the resulting research with the industry.

Through its Certara University, the Company teaches a roster of live online, on-demand, and in-person courses for new and advanced users of our Phoenix software. We continue to have a Professional Certification Program for users who want to have their proficiency and expertise in many of our Software products.

Certara's cultural tenets fuel our mission of Accelerating Medicine to Patients by creating a sense of global togetherness within our Company and across the broader scientific community. Building connections and fostering innovation across the entire scientific community gives the world the best chance of innovating to save lives and preventing patient suffering. That is what Certara is all about, and we are driven to succeed.

Our People and Culture

OUR CULTURAL VALUES

SCIENTIFIC EXCELLENCE

The Certara Drug Development Solutions division actively trains and engages with scientific leaders of the future in the critical areas of Clinical Pharmacology and Pharmacometrics. We invest in giving students real world experience in drug development by working side-by-side with our scientific experts.

The Clinical Pharmacology team in CDDS has been partnering with the Eshelman school of Pharmacy, University of North Carolina since 2020 in the UNC Fellowship program. Students pursuing their PharmD in Clinical Pharmacology spend 1 year in intensive training at UNC and then spend 1 year working alongside our Clinical Pharmacologists tackling some of our client's toughest drug development challenges. Over the past 4 years, we have worked with 7 PharmD students who have gone on to careers with Certara, into industry, or into academic fields.

The Quantitative Scientific Solution team for Certara has one of the largest teams of pharmacometricians in the world. Our team has created opportunities for graduate students interested in becoming Pharmacometricians. In the past 2 years, Certara has led pharmacometrics training in Africa through its Certara Applied Pharmacometrics Training Fellowship.

Over 15 graduate students from across Africa are in an immersive program that accelerates their understanding of drug development and mastery of pharmacometrics. The first program consists of an intensive 3-month virtual training program that consists of classroom training and hands-on assignments developed by Certara Pharmacometricians. A subset of this training group will be selected for a cohort who will work side-by-side with Certara Pharmacometricians supporting their work. Our fellows' efforts result in publishable scientific posters that are co-authored with their mentor. These grad students have gone on to work within industry and directly with Certara.

In the US, the QSS team has launched a partnership with University of Florida. We are currently teaching two courses at University of Florida; Course 1: Introduction to Applied Pharmacokinetics: dive into the intricate science of pharmacokinetics and its practical applications; Course 2: Pharmacometrics Using Pirana-NONMEM and RsNLME. Additionally, we have a PhD intern and Post-doc Intern working with our Pharmacometrics experts within the business. This immersive, hands-on work allows for our interns to see the challenges and innovative approaches needed to solve the challenges to advance medicines to the patients who need it.

Our People and Culture

ENGAGING OUR EMPLOYEES

WE RECOGNIZE THAT DRIVING OUR CULTURE, LIVING OUR VALUES AND ENGAGING OUR PEOPLE ARE ESSENTIAL FOR GROWTH IN A RESEARCH-BASED ORGANIZATION. In 2023, Certara conducted an annual all-employee engagement survey to gauge employee sentiment and identify opportunities for improvement. This survey and the follow-up actions that accompany it are critical to maintaining a comprehensive understanding of employee engagement and ensuring that Certara employees feel connected to the Certara mission and empowered to build long-lasting, fulfilling careers within the organization.

As we continue to respond to the voice of our employees and the feedback that they are providing, our goal is to continuously improve engagement with employees.

Great Place To Work® Certified MAY 2024–MAY 2025 USA ™

Certara was certified as a Great Place to Work in 2024

This prestigious award recognizes employers with exceptional employee engagement and whose employees have highly favorable views regarding company practices and culture. Great Place To Work® Certification™ helps companies attract and retain top talent, improve productivity, enhance reputation, and gain valuable insights into their workplace culture.

Our People and Culture

EMPLOYEE HEALTH AND WELLBEING

CERTARA TAKES A HOLISTIC APPROACH TO EMPLOYEE HEALTH AND WELL-BEING and offers a multitude of benefits and programs to support employees.

Certara provides a very competitive compensation package, which includes (depending on location) pension/retirement savings benefits, life insurance, income protection, healthcare, and gym payments. In addition, we offer at least 25 days of vacation outside the US, plus national holidays, and a generous sickness policy. Absence is proactively managed with a return-to- work mindset, but illness occurs, and employees are supported through it. In the US, Certara has an unlimited vacation policy. Certara also provides financial support for maternity and paternity leave and assistance to new mothers returning to work.

The Company also offers global health and welfare plans, ensuring that all our employees receive coverage. While there is some variation by region and country, Certara provides a competitive benefits program in each market. Certara also has a global employee assistance program that provides access and support for employees on a wide variety of topics. This program offers confidential assessments, counseling, referrals, and follow-up services to employees needing support. Additionally, two team members are certified mental health responders through the National Council for Mental Wellbeing.

In early March 2020, we instituted a global work-from-home policy to ensure the health of our employees and local communities during the COVID-19 pandemic. As a result, all employees transitioned to working from home, and we began providing virtual wellness and mental health support programs, such as virtual fitness challenges, hydration challenges, live and on-demand yoga, and meditation classes. These offerings are featured, along with other global employee resources, on the Certara Wellness & Lifestyle website.

Our staff is also well-equipped to work remotely while engaging with our customers and advancing business objectives. In recent years, many employees have adopted a hybrid schedule, working part-time in the office and part-time remotely. All employees that have returned to the office have completed re-entry training on safety and reporting protocols to ensure that they remain healthy.

To help employees feel connected and supported while working from home, Certara has organized regular meetings with colleagues overseas. These virtual get-togethers have included coffee meetings, team-building events, a recipe exchange, and a holiday party where employees decorated gingerbread houses.

Our People and Culture

COMMUNITY IMPACT

CERTARA EMPLOYEES ARE COMMITTED TO GIVING BACK TO THE COMMUNITIES where they live and work in creative ways, which leverage their skills and strengths.

To help get children interested in science, technology, engineering, and mathematics (STEM) careers from an early age, we participate in a pen pal program called "Letters to a Pre-Scientist," which pairs employees with 5th to 10th grade students in low-income communities. Through this letter-writing program, we inspire and empower students to pursue their own STEM careers. Certara also hosts work experience weeks for local school children who would like to gain hands-on industry experience in science and software development.

Certara employees also conduct presentations and participate in recruitment fairs at local universities to encourage students to embark on drug development and regulatory careers.

In 2023, our Data Sciences organization selected local Teachers' school supply wish lists and fulfilled them.

In keeping with the company's focus, we believe it is important to support the health and wellbeing of our local communities.

Our People and Culture

DIVERSITY, EQUITY AND INCLUSION

CERTARA'S INNOVATIVE CULTURE IS GROUNDED IN RESPECT FOR DIVERSE IDEAS AND PERSPECTIVES AND ADVANCEMENT OF DIVERSITY, EQUITY, AND INCLUSION. We promote a positive and productive work environment free from discrimination, harassment, and retaliation, and where everyone is treated fairly and with dignity and respect. To help achieve that goal, all Certara employees participate in unconscious bias training as part of the Company's new hire compliance curriculum.

Certara ensures that all staff have equal opportunities for career advancement. To this end, all promotion opportunities are posted and announced openly, and pay is reviewed regularly to ensure fair practices. Furthermore, job training programs covering technical and soft skills are available on an ongoing basis for employees who want to refine specific skills. In addition, all employees participate in a formal performance management process and receive career coaching and counseling as necessary.

Certara staff who participate in screening and selecting new hires receive ongoing training to maintain and improve those nondiscriminatory practices, including participating in biannual Office of Federal Contract Compliance / Local Job Network training. Additionally, Certara has developed several recruitment programs in the US to attract diverse applicants, including females, minorities, veterans, and individuals with disabilities.

Certara also encourages minority and female employees to refer job applicants. Applications from minorities and women are also encouraged during school recruiting efforts. We embrace diversity and strive to include our own Certara employee photos in recruiting brochures and on career pages to highlight the Company's diverse culture. In addition, new job openings are advertised in publications written for minority groups and women.

GENDER AND ETHNICALLY REPRESENTATION

GLOBAL FEMALE TALENT REPRESENTATION

	FY23
FEMALE EMPLOYEES	52%
FEMALE MANAGERS AND ABOVE	48%
FEMALE NEW EMPLOYEE HIRES	46%

U.S. ETHNICALLY DIVERSE TALENT REPRESENTATION

	FY23
ETHNICALLY DIVERSE	29%
ETHNICALLY DIVERSE MANAGERS AND ABOVE	22%
ETHNICALLY DIVERSE NEW EMPLOYEE HIRES	37%

Corporate Governance and Compliance

BOARD OF DIRECTORS

Certara's board of directors is responsible for overseeing the activities and affairs of the Company, as reported to the board by our CEO and senior management team.

BOARD OVERSIGHT OF ESG MATTERS

The board ensures that the Company is committed to and is pursuing activities that support responsible ESG policies. The board has delegated the primary oversight of ESG matters to the Nominating and Corporate Governance Committee, who works with senior management, through our ESG Steering Committee, to develop and implement a long-term ESG strategy.

BACKGROUND AND EXPERIENCE OF DIRECTORS

Our board members have been selected based on their qualifications, strength of character, judgment, industry knowledge and experience. When considering new nominees, in addition to those qualities, the board considers other factors, including age, diversity of background, existing commitments to other businesses, service on other boards of director or similar governing bodies of public or private companies, potential conflicts of interest, corporate governance background, financial and accounting background, executive compensation background, and the overall size, composition and combined expertise of the exiting board of directors. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business. Once appointed, directors serve until their term expires, they resign, they are removed by the stockholders, or achieves the age of 75.

BOARD STRUCTURE

Our board of directors currently consists of nine individuals, divided into three classes of directors, with staggered three-year terms. One class of directors is elected at each annual meeting of stockholders. The board meets regularly with senior management, typically 4-5 times per year, in addition to special ad hoc meetings that may be called from time to time by either the chairman of the board or as requested by our CEO.

Our leadership structure separates the offices of chief executive officer and chairperson of the board of directors, with Dr. William Feehery serving as our CEO and Mr. James Cashman serving as chairman of the board. We believe this is appropriate as it provides Dr. Feehery with the ability to focus on our day-to-day operations while allowing Mr. Cashman to lead our board of directors in its fundamental role of providing advice to and oversight of management.

Our board of directors has no firm policy with respect to the separation of the offices of CEO and chairperson of the board of directors. It is the board of directors' view that rather than having a rigid policy, the board, upon consideration of all relevant factors and circumstances, will determine whether the two offices should continue to be separate. We do have a policy that if the chairperson of the board is also the chief executive officer or is a director who does not otherwise qualify as an "independent director," the independent directors will elect from among themselves a Lead Director of the board.

BOARD DEMOGRAPHICS ON GENDER

3	4	2
WOMEN	MEN	DID NOT DISCLOSE

Corporate Governance and Compliance

BOARD OF DIRECTORS

COMMITTEES OF THE BOARD OF DIRECTORS

The standing committees of our board of directors consist of an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. Our chief executive officer and other executive officers regularly report to the non-executive directors and the Audit, the Compensation and the Nominating and Corporate Governance Committees to ensure effective and efficient oversight of our activities and to assist in proper risk management and the ongoing evaluation of management controls.

COMPENSATION COMMITTEE

The purpose of the Compensation Committee is to assist our board of directors in discharging its responsibilities relating to, among other things, (1) setting our compensation program and compensation of our executive officers and directors, including reviewing the Company's efforts with respect to pay equity, (2) administering our incentive and equity-based compensation plans and (3) preparing the compensation committee report required to be included in our proxy statement under the rules and regulations of the SEC.

NOMINATING AND CORPORATE GOVERNANCE COMMITTEE

In addition to overseeing the Company's ESG programs and strategies, the purpose of our Nominating and Corporate Governance Committee is to assist our board of directors in discharging its responsibilities relating to (1) identifying individuals qualified to become new board members, consistent with criteria approved by the board of directors, (2) reviewing the qualifications of incumbent directors to determine whether to recommend them for reelection and selecting, or recommending that the board of directors select, the director nominees for the next annual meeting of stockholders, (3) identifying board members qualified to fill vacancies on any committee of the board of directors and recommending that the board of directors appoint the identified member or members to the applicable committee, (4) reviewing and recommending to the board of directors corporate governance principles applicable to us, and (5) overseeing the evaluation of the board of directors and management.

Corporate Governance and Compliance

BOARD OF DIRECTORS

AUDIT COMMITTEE

The purpose of the Audit Committee is to prepare the audit committee report required by the SEC to be included in our proxy statement and to assist our board of directors in overseeing and monitoring (1) the quality and integrity of our financial statements, including oversight of our accounting and financial reporting processes, internal controls and financial statement audits, (2) our compliance with legal and regulatory requirements, (3) our independent registered public accounting firm's qualifications, performance and independence, (4) our corporate compliance program, including our code of conduct and anti-corruption compliance policy, and investigating possible violations thereunder, (5) our risk management policies and procedures, including those relating to data privacy and protection and cybersecurity and (6) the performance of our internal audit function.

DIRECTOR INDEPENDENCE

Our board of directors has affirmatively determined that each of our directors, other than our CEO, Dr. Feehery, qualifies as "independent" in accordance with SEC guidance and Nasdaq rules. Our Audit Committee members also qualify as independent under the heightened standard of independence for Audit Committee members. In making its independence determinations, our board of directors considered and reviewed all information known to it, including information identified through directors' questionnaires.

CORPORATE GOVERNANCE GUIDELINES

Our board of directors has adopted corporate governance guidelines which describe the principles and practices that our board of directors will follow in carrying out its responsibilities. These guidelines cover a number of areas including the role and responsibilities, size and composition of the board, independence of directors, selection of chairperson of the board and chief executive officer, conflicts of interest, change in present job responsibility, director orientation and continuing education, lead director, term limits, board meetings, board committees, expectations of directors, management succession planning, evaluation of board performance, board compensation, communications with stockholders, implementation of stockholder agreements, and communications with non-management directors.

Our board of directors has also implemented a Delegation of Authority policy to clearly delineate the day-to-day activities that may be performed and executed by senior management from more material or strategic decisions that require prior notice and approval by the board of directors.

STOCK OWNERSHIP REQUIREMENTS

To further align the interests of our board members with the interests of our stockholders, our board of directors has adopted director stock ownership guidelines for non-employee directors. Each non-employee director who receives a cash and/or stock retainer for his or her service as a director has a target minimum common stock ownership requirement of five times the value of the annual cash retainer (excluding committee retainers) paid by us to the non-employee director pursuant to our then current director compensation plan. Non-employee directors are expected to meet this minimum target within five years of becoming subject to the ownership guidelines.

Corporate Governance and Compliance

ETHICS AND COMPLIANCE

WE HAVE ADOPTED A CODE OF CONDUCT THAT APPLIES TO ALL EMPLOYEES, EXECUTIVE OFFICERS AND DIRECTORS, addressing legal and ethical issues that may be encountered in carrying out their duties and responsibilities, including the requirement to report any conduct they believe to be a violation of the Code of Conduct. Our Code of Conduct covers a wide range of ethical and legal issues, including business conduct, conflicts of interest, record keeping, confidentiality, discrimination and harassment, health and safety, and fair competition, among other topics. We require all new employees to review and understand the Code of Conduct and regularly conduct training for all employees on our Code of Conduct.

We encourage all of our employees to ask questions, raise concerns, or report misconduct, through a number of avenues, including use of our compliance hotline, and we have a strict non-retaliation policy.

In addition to our Code of Conduct, we have adopted a number of other related policies, including our policies on Anti-Bribery/Corruption, Anti-Harassment and Discrimination, Quality, Insider Trading, External Communication, Data Privacy and Protection, Environmental Stewardship, and Sustainable Procurement, and have adopted a separate Human Rights Statement.

99%

TRAINING OF ALL EMPLOYEES ON CODE OF CONDUCT

TOPICS THAT EMPLOYEES RECEIVE REGULAR TRAINING ON

In addition to Code of Conduct training, our employees receive regularly training on the following areas:

- Insider trading
- Global anti-corruption and anti-bribery
- Unconscious bias
- IT security
- Data protection basics
- Recognizing and avoiding social engineering
- Harassment prevention

Corporate Governance and Compliance

DATA PRIVACY AND CYBERSECURITY

CERTARA IS COMMITTED TO PROTECTING THE PRIVACY AND SECURITY OF THE PERSONAL INFORMATION THAT WE COLLECT OR USE WHILE DOING BUSINESS. We do so in accordance with all applicable data protection and privacy laws, rules and regulations, and regulatory guidance, guidelines, and requirements in the jurisdictions where our services are rendered and/or the parties are based.

We have operationalized data privacy, security, and compliance to build digital trust. We have established a comprehensive Data Security and Privacy Program and governance model to achieve that goal, which allows us to respond rapidly with new policies, processes, or applications to meet changing needs or regulations.

DATA PRIVACY AND SECURITY GOVERNANCE

Our data security and privacy program is led by Certara's Head of Compliance and Data Privacy. They are responsible for the program's strategy, design, execution, and reporting.

The Compliance and Data Privacy function reports under the Information Technology organization with reporting responsibility to Certara's Executive Leadership Team. They, along with the Certara Legal team, are responsible for ensuring that Certara complies with security and privacy regulations and controls and provides regular updates to the Audit Committee of our board of directors.

PROGRAM STRUCTURE

Certara's Security and Privacy Program ensures that information assets are protected from threats, whether internal or external, deliberate or accidental.

We use a third-party privacy, security, and data governance platform to evaluate our privacy impact assessments and our processes and have conducted a data mapping inventory of our processes, vendors, and assets. We also manage data participant requests through that system.

Certara's Information Technology controls adhere to the National Institute of Standards and Technology ("NIST") Risk Management Framework, the NIST Cybersecurity Framework, and the NIST Privacy Framework. Certara's Corporate Information Technology and Commercial Software offerings are ISO 27001:2013 certified.

"Data protection and cyber security are important areas that we prioritize and manage proactively. As a testament to the success of our program, we have not have experienced any reportable data breaches."

– Leif Pedersen, President of Software Officer

Corporate Governance and Compliance

DATA PRIVACY AND CYBERSECURITY

1

PERSONAL DATA LIFECYCLE MANAGEMENT

Certara limits the collection, creation, use, dissemination, maintenance, retention, and/or disclosure of personal data to those that are legally authorized, relevant, and deemed "reasonably necessary" for the proper performance of our business. We maintain appropriate technical and organizational measures to keep personal information secure and protect against unauthorized or unlawful processing and against accidental loss, destruction, or damage. Personal information (and sensitive personal information) is only retained for the period that is necessary to perform the required function and comply with data protection laws and Certara's contractual obligations.

2

PRIVACY CHOICES AND DATA PARTICIPANT RIGHTS/REQUESTS

Certara allows individuals to choose how their personal data are handled as required by applicable data protection and privacy laws and regulations for the locations where we conduct business. Individuals have the following choices and rights regarding their personal data that we collect and process: right of access, accuracy, erasure, and portability. They also have the right to restrict processing, object or opt-out.

3

TRANSPARENCY AND PRIVACY NOTICES

We communicate transparently with all data participants about our privacy practices, including gaining active consent from people when their personal data are collected. We declare the lawful basis for collection, use, maintenance, and sharing of personal data. This includes staff documentation and public notices on all our websites, and digital services regarding the collection, creation, use, dissemination, maintenance, retention, onward transfer and/or disclosure of personal data. Link to our privacy notice.

4

SECURITY AND PRIVACY AWARENESS TRAINING

We train our employees to be aware of the security and privacy risks associated with their roles and understand the applicable statutory, regulatory, and contractual compliance requirements related to the security and privacy of systems and data where they work. All new Certara employees receive essential security and privacy training, which is reinforced through mandatory annual supplemental training. We also conduct additional role-based training, as required to ensure adherence to current and applicable standards for our team members.

5

SECURITY AND PRIVACY BY DESIGN AND DEFAULT

We employ a project management framework which includes the design to protect personal data and considers the intended use of those data. We balance the need to process, collect, and store this information against any person's privacy risks. Our controls are commensurate with the risk and magnitude of the harm that would result from the unauthorized access, use, modification, loss, or dissemination of the personal data we collect.

6

REGULATORY OBLIGATIONS

We use commercially reasonable efforts to protect personal information to the extent required by applicable data protection and privacy laws and regulations for locations where we conduct business and where our clients use our services. In certain circumstances, Certara may be obliged to disclose personal data under national or international law, or at the request of governmental agencies. We seek to comply with such requests, where doing so will not adversely impact people's privacy or materially affect business.

Corporate Governance and Compliance

DATA PRIVACY AND CYBERSECURITY

7

THIRD-PARTY CONTRACTUAL OBLIGATIONS

We include privacy requirements in our contracts, specifically in data protection agreements and approved standard contractual clauses, which establish privacy roles and responsibilities for clients, contractors, service providers and third-party vendors.

8

DATA SECURITY GOVERNANCE

In most cases when we receive study data from our clients, they are pseudonymized (or key-coded) to mask the participants' identity. Pseudonymization techniques do not exempt Certara from data protection laws, however they do help us meet our data protection obligations.

We employ cryptographic technologies to protect sensitive business data against loss, unauthorized access, or disclosure. This applies to sensitive data, regardless of whether they are at rest or in transit.

We also have a formal process to guide our response to any incidents that impact information technology and service operations. This includes identification and analysis of known and, to the extent possible, suspected security and privacy-related incidents. The process provides direction for the containment, mitigation, and recovery from potentially harmful effects of incidents, and the formal documentation and communication of incidents and their outcomes.

As a testament to the success of this program, Certara has not experienced any reportable data breaches. We have not received any materially negative audit results or incurred any fines, and have promptly responded to all requests by individuals to delete their data.

Corporate Governance and Compliance

QUALITY PRODUCTS AND SERVICES

CERTARA CONTINUOUSLY AND INTENTIONALLY FOSTERS A CULTURE FOCUSED ON QUALITY.

Across every aspect of Certara, we employ a proactive risk-based quality management system to ensure best practices moderate operational decisions, compliance with regulations, and customer quality expectations are met.

Our electronic Quality Management System ("eQMS") provides an industry leading foundation for managing an effective QMS. The system is validated, 21 CFR Part 11 compliant, and is used by all Certara business units. Certara's eQMS serves as a document management solution for the review and approval of all policies, standard operating procedures, work instructions, forms and templates. As our training management system, it serves as the repository for training records on Certara processes organization-wide. It is also the home for any quality events, process deviations records, and audit (internal and external) records as well as emerging corrective and preventive actions ("CAPAs").

The reporting functions of our QMS can produce real time and regular cadence reports on content such as training compliance across the entire company. Likewise, CAPAs, audits, and other quality metrics are available in real time and at regular intervals enabling evidence-based decisions from Leadership.

Our clients routinely audit our systems and processes. During the last calendar year, we completed more than 300 customer audits, effectively leveraging our remote audit capabilities. The success rate of these audits is a testament to Certara's commitment to define the processes & controls in place to ensure the reliability and validity of our products and services.

OUR QMS PRINCIPLES INCLUDE THE FOLLOWING:

- **Ethical conduct.** Certara intentionally fosters a culture focused on accountability, quality, and continuous improvement
- **Risk Management.** Awareness of and response to identified risks are integrated into Certara's processes to facilitate the continual improvement and provide a structure for consistent quality products and services
- **Process Management.** Certara has implemented an electronic Quality Management System to provide an industry leading foundation for the governance of our interrelated processes that function as a coherent system
- **Accountability.** Employees receive the required training to comply with company policies, industry standards, and legal guidelines through Certara's eQMS
- **Internal Stakeholder Engagement.** Facilitate the engagement of people in achieving the organization's quality objectives through our corporate eQMS. A robust training program that enables recognition, empowerment, and enhancement of Certara's workforce
- **External Stakeholder Engagement.** Commitment to continuous improvement aligning with industry best practices and regulatory guidelines to meet the needs of our clients. Deliver reliable, compliant, and high-quality products and services to our clients and stakeholders.

Our Environmental Impact

CERTARA IS COMMITTED TO MINIMIZING ANY NEGATIVE IMPACTS OUR BUSINESS MAY HAVE ON THE ENVIRONMENT.

We strive to improve our environmental performance over time and to initiate projects and activities that will help preserve and protect our planet, and we will proactively demonstrate our commitment to stewardship and sustainable development. This commitment to the environment extends to our customers, our staff, and the community in which we operate.

As expressed in our Environmental Policy, we pledge to:

- Comply with all applicable environmental, health, and safety laws, regulations, and other requirements
- Prevent pollution whenever possible
- Continually improve our environmental performance
- Provide training to our employees on relevant environmental programs and empower them to contribute and participate
- Communicate our environmental commitment and efforts to our customers, staff, and community
- Implement effective waste minimization programs to reduce, reuse, and recycle materials and
- Continually improve over time by measuring our most significant environmental impacts.

Certara operates within a limited physical footprint, consisting of office-based facilities with no manufacturing operations. As of the end of 2023, we leased approximately 170,000 square feet of office space in 24 locations across the globe. Even before the COVID-19 pandemic, we allowed our employees great flexibility in working from home and had begun to reduce the number and size of our offices. We realized early in the pandemic that we can successfully operate in a virtual environment. However, we also believe there is great value in maintaining central hubs where our employees can meet together or with clients. We will continue to move toward a balance of minimizing our office footprint while ensuring our employees have convenient opportunities to collaborate and form strong bonds. We will continue to allow substantial flexibility in when and how frequently our employees commute to work, which we believe will further reduce our aggregate impact on the environment. We also track and analyze our office utilization to help us identify ways to reduce our total square footage, as well as minimize the energy and water consumption occurring at our facilities.

Our Environmental Impact

We have a dedicated facilities management department that has introduced several programs intended to support our commitment to environmental stewardship:

- Paper recycling
- Use of water filter machines instead of water delivery systems
- Bulk purchases of office supplies to avoid multiple deliveries
- Discourage use of single use plastics by stocking kitchen spaces with full reusable (stainless) cutlery, dishes, glasses, etc.
- Supply coffee machines that use recyclable coffee pods
- Recycle or reuse of furniture, and donation of furniture where possible when vacating space
- Printers are set to "Print Both Sides" as default
- Notify building management on occupancy trends to allow for better utilization of the HVAC and electrical costs
- Transitioning from plastic security badges to utilizing electronic access applications and
- Recycling/donation of computer hardware, including laptops, monitors, keyboards, and docking stations.

Air travel by our employees is another important area where we believe we can have a positive impact on the environment. Our goal is to ensure that we limit air travel for business critical activities.

SUSTAINABLE PROCUREMENT

Certara believes that it is important for our vendors to share our commitment to sustainability, which is why we have adopted a Sustainable Procurement policy, through which we identify and manage the environmental, social, and economic impacts within our supply chain. More specifically, our policy dictates that we weigh the following factors when comparing and selecting material vendors:

- Does the supplier practice sustainable and ethical practices within their organization and drive such practices within their own supply chain?
- Does the supplier have programs in place that actively reduces their environmental footprint through conservation of resources, including the use of energy, water and materials?
- Can the supplier demonstrate how they reduce their carbon footprint through waste minimization, both within their operations and through reduction of packaging?
- Does the supplier reduce the impact of deliveries by maximizing local sourcing?

Our Environmental Impact

SCOPE 1, 2, 3 GREEN HOUSE GAS (GHG) METRICS

Energy we expend directly from physical footprint (HVAC, electricity) as well as applicable upstream and downstream activities (business travel, employee commute, etc).

2022-2023 SCOPES 1-3 EMISSIONS

Scope	Description	2022 GHG Emissions (mt CO2e)	2023 GHG Emissions (mt CO2e)	YOY % Difference
Scope 1	Natural Gas and Refrigerant	441.26	363.34	-18%
Scope 2 Location-based	Purchased Electricity using regional emission factors	837.88	816.41	-3%
Scope 2 Market-based	Purchased Electricity using utility-specific emission factors and accounting for Renewables	851.08	881.58	4%
Scope 3	All upstream and downstream activities that are applicable to Certara	8,385.89	7,765.85	-7%
	Total Location-based Emissions	**9,665.03**	**8,945.60**	**-7%**
	Total Market-based Emission	**9,678.23**	**9,010.77**	**-7%**

2023 SCOPES 1-3 INVENTORY



Our Environmental Impact

SCOPE 1, 2, 3 GREEN HOUSE GAS (GHG) METRICS

Energy we expend directly from physical footprint (HVAC, electricity) as well as applicable upstream and downstream activities (business travel, employee commute, etc).

2023 SCOPES 1-3 INVENTORY



2022-2023 SCOPE 3 EMISSIONS BY CATEGORY

Scope	Description	2022 GHG Emissions (mt CO2e)	2023 GHG Emissions (mt CO2e)	YOY % Difference
1-Purchased Goods & Services	Production and sales for products, i.e. suppliers	5,395.85	5,511.54	2%
2-Capital Goods	Purchases of final products with extended life.	633.43	296.76	-53%
3-Fuel-and-Energy-Related Activities	Extraction, production, transportation of fuels and energy not accounted for in Scope 1 & 2.	356.14	355.08	-0.3%
5-Waste Generated	Estimates for disposal and treatment of landfill and recycling waste from Certara facilities.	6.58	7.19	9%
6-Business Travel	Transportation of employees for business. Incl. air, ground, and hotel. Using mileage data or estimated mileage from expense data, assumptions, and research.	474.72	770.28	62%
7-Employee Commute	Personal commuting of employees between their home and workspaces as well as remote work.	1,515.37	821.31	-46%
8-Upstream Leased Assets	Assets leased from other entities, i.e. leases/subleases. Includes emissions provided by cloud data servers for Certara's software and operations.	3.81	3.69	-3%
	Total Scope 3 Emissions	**8,385.98**	**7,765.85**	**-7%**

Awards and Accolades

WORKPLACE DISTINCTIONS

PharmaVoice 100
Top Industry Leaders

2024 HONOREE

Congratulations
Chris Bouton

CATEGORY
Tech and AI wizards

FORTUNE
2024
BEST WORKPLACES
in Biopharma™

FORTUNE
2024
BEST WORKPLACES
in New York™
Including NJ, PA, CT

Champions
OF BOARD DIVERSITY
2024
Bronze: 30% or More
Women on Their Boards
The Forum of Executive Women

2024 EXCELLENCE IN INNOVATION AND CREATIVITY AWARD

Oxana Iliach
Senior Director, Regulatory Strategy
Certara

CERTARA
Accelerating Medicines Together
2024
Champion of
Board Diversity in Philadelphia
The Forum of Executive Women

Great Place To Work®
Certified
MAY 2024–MAY 2025
USA
™

CERTARA

CERTARA REMAINS COMMITTED TO UNDERSTANDING, MONITORING, AND MANAGING OUR SOCIAL AND ENVIRONMENTAL RESPONSIBILITIES AND DATA PRIVACY TO SUPPORT SUSTAINABLE GROWTH.